Cardiovascular developments: patent highlights July to December 2006.
This overview provides a follow-up to a previously published paper on patent highlights of cardiovascular developments for January to June 2006. A period of six months could not have altered the fundamental preliminaries of the developmental challenges which cardiovascular disorders present to the pharmaceutical and biotechnology industry, and it was not expected that scientific insight would make quantum leaps during this brief interval. What makes such a repeat analysis nevertheless highly meaningful, beyond providing just another set of recent patent references, is the objective of validation--investigating whether the patterns that were observed during the initial review of the first half of 2006 actually represent established modalities of innovative industry efforts in the cardiovascular field. This objective was met by replicating the previous search of Thomson Scientific's Investigational Drugs database, and by using the same categorization of identified intellectual property disclosures.
Mucke
Hermann A M
HA
HM Pharma Consultancy, Enelkelstrasse 28/32, A-1160 Wein, Austria. office@hmpharmacon.com
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004345:Drug Industry / Q000379:methods / Q000706:statistics & numerical data*; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D010330:Patents as Topic / Q000706:statistics & numerical data*; D012083:Renin / Q000737:chemistry / Q000627:therapeutic use; D013997:Time Factors; D000092502:Renin Inhibitors
D005343:Fibrinolytic Agents; D012083:Renin; D000092502:Renin Inhibitors